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The effect of spironolactone on calcineurin
inhibitor induced nephrotoxicity: a
multicenter randomized, double-blind,
clinical trial (the SPIREN trial)
Line Aas Mortensen1,2*, Helle C. Thiesson1,2, Birgitte Tougaard3, Martin Egfjord4, Anne Sophie Lind Fischer5
and Claus Bistrup1,2
Abstract
Background: Calcineurin inhibitor induced nephrotoxicity contributes to late allograft failure in kidney transplant
patients. Evidence points towards aldosterone to play a role in the development of fibrosis in multiple organs.
Animal studies have indicated a beneficial effect of mineralocorticoid receptor antagonists preventing calcineurin
inhibitor induced nephrotoxicity. Only few studies have explored this effect in humans. The objective of this study
is to evaluate the effect of spironolactone on glomerular filtration rate and fibrosis in kidney transplant patients.
Method: Prospective, double-blind, randomized, clinical trial including 170 prevalent kidney transplant patients.
Patients are randomized to spironolactone 25–50 mg/day or placebo for three years. Primary outcome is glomerular
filtration rate evaluated by chrome-EDTA clearance. Secondary outcomes are 24-h protein excretion, amount of
interstitial fibrosis in renal allograft biopsies, and cardiovascular events. As an exploratory outcome, we aim to
identify markers of fibrosis in blood and urine.
Discussion: Long term allograft survival remains a key issue in renal transplantation, partly due to calcineurin inhibitor
induced nephrotoxicity. Evidence from animal- and small human studies indicate a beneficial effect of mineralocorticoid
receptor antagonism on renal function and fibrosis. This study aims to test this hypothesis in a sufficiently powered
randomized clinical trial. Results might influence the future management of long term allograft survival in renal
transplantation.
Trial registration: ClinicalTrials.gov identifier (05/17/2012): NCT01602861. EudraCT number (05/31/2011): 2011–002243-98.
Keywords: Aldosterone, Mineralocorticoid, Kidney transplantation, Cyclosporine A, Tacrolimus, IFTA, Fibrosis, Glomerular
filtration rate
Background
Background and rationale
The introduction of calcineurin inhibitors (CNI) cyclospor-
ine and tacrolimus as part of immunosuppressive regimens
in kidney transplantation has significantly improved short
term allograft survival and function [1, 2], but continuous
exposure to CNI can result in renal fibrosis ultimately
leading to chronic allograft failure. CNI nephrotoxicity is
partly caused by vasoconstriction, thereby reducing renal
blood flow and inducing oxidative stress, but also CNI
directly increase the pro-fibrotic factor transforming
growth factor β (TGF-β), apoptosis and macrophage infil-
tration [3]. Early reports indicated a prevalence of chronic
CNI nephrotoxicity of up to 100% after 10 years of cyclo-
sporine treatment [4], although a recent follow up has in-
dicated less nephrotoxicity of modern, tacrolimus-based
immunosuppressive protocols [5]. Nevertheless, improv-
ing long term allograft function remains a key challenge in
renal transplantation.
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The mineralocorticoid hormone aldosterone contrib-
utes to deleterious pro-fibrotic processes in several or-
gans, including the kidneys [6, 7]. Aldosterone exerts its
effects partly via the intracellular mineralocorticoid re-
ceptor (MR). Signaling via the MR regulates salt- and
water balance, but also prompts inflammation, vasocon-
striction and oxidative stress, which ultimately leads to
tissue fibrosis [7]. Several large scale studies in congest-
ive heart failure have highlighted the beneficial effect of
MR antagonism on survival [8, 9] – partly explained by
decreased myocardial fibrosis [10]. In chronic kidney
disease, MR antagonism has shown beneficial effects re-
ducing proteinuria, but no study has been sufficiently
powered to investigate the effect on kidney function
[11]. Evidence from animal models of CNI nephrotox-
icity suggests a beneficial effect of MR antagonism on
renal blood flow [12, 13], glomerular filtration rate (GFR)
[12–18] and renal fibrosis [15–18].
Only a few studies have explored the potential of MR
antagonism in kidney transplant recipients. A recent
randomized clinical trial included 24 pediatric kidney
transplant patients with biopsy-proven chronic allograft
nephropathy and did not find a significant effect of
eplerenone for 24 months versus placebo regarding GFR,
proteinuria and fibrosis. The study was, however, under-
powered [19]. One open-label study of 11 kidney transplant
patients found significantly reduced levels of proteinuria
after 6 months of spironolactone treatment despite un-
altered blood pressure [20]. These findings were supported
by a retrospective cohort study of 140 proteinuric kidney
transplant patients concurrently treated with spironolac-
tone [21]. Additionally, it has been shown that eplerenone
given one day before and three days after the trans-
plantation reduces markers of oxidative stress related
to ischemia/reperfusion [22]. Hence, current evidence
points towards beneficial effects of MR antagonism in kid-
ney transplant patients. This remains to be confirmed in a
sufficiently powered prospective trial.
Objectives and design
The SPIREN trial is an investigator initiated nationwide,
multicenter, randomized, double-blind, placebo-controlled
clinical trial designed to test the hypothesis that addition
of the MR-antagonist spironolactone to standard therapy
in prevalent kidney transplant patients will improve long
term kidney function and reduce allograft fibrosis.
Methods
One hundred seventy kidney transplant patients will be
included from four Danish hospitals covering all Danish
renal transplant centers (Odense, Copenhagen and Aarhus).
Patients are recruited from outpatient clinics in the
Departments of Nephrology at Odense University Hospital,
Kolding Hospital, Rigshospitalet, Copenhagen and Aarhus
University Hospital, respectively. Eligibility criteria are
listed in Table 1.
Wide eligibility criteria have been chosen to obtain a
high generalizability of the results. This study includes
renal transplant patients with a stable kidney function at
the time of inclusion. Even in stable patients, a gradual
deterioration of renal function is expected. Previous
studies have found an average rate of decline of glom-
erular filtration rate in of 1–3 mL/min/year [23–26].
Hence, we chose a follow up of 3 years.
Patients are randomized 1:1 to spironolactone (Spirix®)
or placebo for three years. Initial dosage is 25 mg once
daily, which is doubled after three months, if tolerated
well. At inclusion and yearly hereafter a standard
workup is performed including chrome-EDTA clearance,
24-h urine collection, electrocardiogram, 24-h ambulatory
blood pressure measurement and blood- and urine sam-
ples (Fig. 1). Anonymized samples are stored at − 80 °C
until analyses. In a subgroup (n = 50) graft biopsies will be
performed at inclusion and after two years. All registrered
variables are listed in Table 2.
Side effects, adverse events and compliance to the
study drug are evaluated at project visits every three
months. Compliance is evaluated by counting tablets.
Outcome
Outcomes are summarized in Table 3.
The primary endpoint is renal function evaluated by
chrome-EDTA clearance, in which glomerular filtration
rate is calculated from the area under the plasma clearance
curve after a single intravenous doses of 51CrEDTA. Plasma
concentrations of 51CrEDTA can be determined with a
single blood sample by measuring residual radioactivity 4 h
after the injection or by multiple samples 4, 5 and 6 h
after the injection. For centers using a single blood
sample after 4 h, an additional blood sample is performed
24 h after the injection in male patients with plasma
creatinine ≥200 μmol/L and female patients with plasma
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Age > 18 years Former intolerance of
spironolactone
Tacrolimus/cyclosporine treatment Potassium binder or digoxin
treatment
Proteinuria < 3 g/day Pregnancy or planned pregnancy
Creatinine clearance ≥30 mL/min Clinically relevant organic,
systemic or psychological disorder
Plasma potassium < 5.5 mmol/L Expectation of non-compliance
Negative pregnancy test at inclusion
for women of childbearing potential
and adequate contraception
throughout the trial
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creatinine ≥150 μmol/L. In repeat chrome-EDTA clearance
measurements the coefficient of variation is 8–10% [27].
Secondary endpoints include 24-h urinary protein ex-
cretion, cardiovascular events (death, myocardial infarc-
tion, stroke or peripheral arterial thrombosis) and renal
fibrosis. For the latter, Masson Trichrome stained sections
of kidney allograft biopsies will be used for measuring
Banff chronicity scores and calculating morphologic fibro-
sis by point counting. Point counting provides a quantita-
tive and reproducible estimation of the extent of fibrosis
[28]. In brief, the software systematically selects sections
of renal cortex and superimposes a grid on a computer-
ized image. The extent of fibrosis is determined by count-
ing the fraction of intersection points that overlie fibrotic
areas relative to normal tissue. Limitations of both Banff
scoring and point counting are the risk of sampling error
as well as the somewhat subjective evaluation of fibrosis.
In this study all biopsies will be reviewed by the same
pathologist to avoid inter-observer variability.
As an exploratory outcome we aim to identify possible
biomarkers of fibrosis in blood and urine. Kidney fibrosis is
currently diagnosed by renal biopsy. Besides being time-
consuming, it is an invasive procedure and as such, it im-
plies a risk of complications including bleeding, pain and
infection. Hence, much effort has gone into identifying
non-invasive markers of fibrosis in blood or urine.
The fibrotic process is a cascade of factors including
inflammation, tissue hypoxia and various pro-fibrotic
cytokines and growth factors [29]. Animal studies of
MR antagonism in CNI nephrotoxicity have identified
several markers involved in the fibrogenic process that
were regulated by MR antagonists [30]. Simultaneous
plasma−/urine samples and renal biopsies allow for the
possible identification of non-invasive markers of fibrosis.
Further, studies of markers in blood and urine might con-
tribute to our understanding of the molecular mecha-
nisms of MR antagonism. Specific markers of interest will
be defined when all samples have been obtained.
Safety
Plasma potassium and -creatinine levels are monitored
closely at initiation of therapy and after any dose adjust-
ment. Sustained potassium levels > 5.8 mmol/L will result
in reduction of dosage to 25 mg per day. In case of hyper-
kalemia on 25 mg per day, the patient will be withdrawn
from the study. Potassium binding resins will only be used
to handle cases of acute hyperkalemia, thus chronic treat-
ment with resins is not allowed. Hyperkalemia is regis-
tered as an adverse event in case of an absolute increase
of > 1.5 mmol/L or any increase to a level above
5.5 mmol/L. All significant increases in plasma creatinine
are evaluated by study investigators, and in case of doubt
of the etiology, the study drug is discontinued until renal
function has stabilized. All adverse events registered
throughout participation in the study will be recorded.
Serious adverse events are defined according to Good
Clinical Practice as events that result in death, are life
threatening, require hospitalization, cause prolongation of
existing hospitalization or result in persistent or significant
disability/incapacity. The project safety board continuously
Fig. 1 Participant timeline
Mortensen et al. BMC Nephrology  (2018) 19:105 Page 3 of 7
Ta
b
le
2
A
ll
re
gi
st
er
ed
va
ria
bl
es
Ba
se
lin
e
Ev
er
y
3
m
on
th
s
A
dd
iti
on
al
ly
at
0,
1,
2,
3
ye
ar
s
0
an
d
2
ye
ar
s
(n
=
50
)
D
at
e
of
bi
rt
h
Se
x
H
ei
gh
t
Sm
ok
in
g
N
um
be
r
of
pa
ck
ye
ar
s
Pr
im
ar
y
ki
dn
ey
di
se
as
e
Pr
ev
io
us
di
al
ys
is
Tr
an
sp
la
nt
at
io
n
da
te
N
um
be
r
of
pr
ev
io
us
tr
an
sp
la
nt
at
io
ns
C
om
or
b
id
it
y
A
po
pl
ex
ia
M
yo
ca
rd
ia
li
nf
ar
ct
io
n/
ca
rd
ia
c
re
va
sc
ul
ar
is
at
io
n
H
ea
rt
fa
ilu
re
H
yp
er
te
ns
io
n
D
ia
be
te
s
O
th
er
C
ur
re
nt
m
ed
ic
at
io
n
Sy
m
p
to
m
s
D
iz
zi
ne
ss
Fa
in
tin
g
Sh
or
tn
es
s
of
br
ea
th
G
yn
ec
om
as
ty
Im
po
te
nc
e
O
th
er
s
O
b
je
ct
iv
e
fin
d
in
g
s
Bl
oo
d
pr
es
su
re
(s
ys
to
lic
)
Bl
oo
d
pr
es
su
re
(d
ia
st
ol
ic
)
Pu
ls
e
Bo
dy
w
ei
gh
t
B
lo
od
sa
m
p
le
s
So
di
um
Po
ta
ss
iu
m
C
re
at
in
in
e
A
d
ve
rs
e
ev
en
ts
C
om
p
lia
nc
e
to
st
ud
y
d
ru
g
O
b
je
ct
iv
e
fin
d
in
g
s
H
ea
rt
st
et
ho
sc
op
y
Lu
ng
st
et
ho
sc
op
y
Ed
em
a
EC
G
C
hr
om
e-
ED
TA
cl
ea
ra
nc
e
B
lo
od
sa
m
p
le
s
C
RP
To
ta
lc
ho
le
st
er
ol
H
D
L
LD
L
Tr
ig
ly
ce
rid
e
M
ar
ke
rs
of
fib
ro
si
s
24
h
ur
in
e
sa
m
p
le
C
re
at
in
in
e
cl
ea
ra
nc
e
Pr
ot
ei
nu
ria
U
-s
od
iu
m
U
-p
ot
as
si
um
M
ar
ke
rs
of
fib
ro
si
s
A
m
b
ul
at
or
y
b
lo
od
p
re
ss
ur
e
SB
P
D
BP
SB
P-
da
y
SP
B-
ni
gh
t
D
BP
-d
ay
D
BP
-n
ig
ht
A
ve
ra
ge
pu
ls
e
K
id
ne
y
b
io
p
sy
A
m
ou
nt
of
fib
ro
si
s
(%
)
Ba
nf
f-s
co
re
EC
G
El
ec
tr
oc
ar
di
og
ra
m
,C
RP
C-
re
ac
tiv
e
pr
ot
ei
n,
H
D
L
H
ig
h
de
ns
ity
lip
op
ro
te
in
,L
D
L
Lo
w
de
ns
ity
lip
op
ro
te
in
,S
BP
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
,D
BP
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
Mortensen et al. BMC Nephrology  (2018) 19:105 Page 4 of 7
monitors serious adverse events to identify general study
safety issues.
Withdrawal
Withdrawal criteria include a sustained compliance of
less than 80%, hyperkalemia despite reduction of dosage
or intolerable side effects.
Sample size
Assuming a standard deviation in chrome-EDTA clearance
of 10 mL/min, a sample size of 126 patients (63 in each
group) will be able to detect a difference in chrome-EDTA
clearance of 5 mL/min between the groups with 80%
power and a significance level of 0.05. With an expected
dropout rate of 15%, the planned total was set to 170
patients.
Allocation and blinding
After completing the baseline workup (Fig. 1), patients
are allocated to consecutive randomization numbers.
Randomization has been performed by the pharmacy at
Odense University Hospital in blocks of four. The alloca-
tion code is blinded to both patients and investigators
and is solely known by the pharmacy. Opaque envelopes
containing the individual allocation are available on site
in case of the need for emergency unblinding. If the allo-
cation code is revealed before completing the trial the
patient will be excluded.
Data management
All data will be documented for each visit in the respect-
ive Case Report Form and subsequently entered into the
SPIREN project database. Data will be secured by double
entry. The project database has been developed in cooper-
ation with the Database Unit of the Region of Southern
Denmark and complies with the standards of Good
Clinical Practice.
Statistical methods
All statistical analyses will be done using STATA software.
All generated variables will be documented by do-files.
The main analysis will be performed as intention-to-treat
using last-observation-carried-forward. Sub-analyses will
include per protocol analyses and “best case”/“worst case”
analyses. Where appropriate, variables will be analyzed
using parametric or non-parametric tests.
Trial status
The first patient was included in January 2013. An interim
analysis was performed in September 2015 including 40
patients after two years of participation [31]. The interim
analysis evaluated the rates of decline in kidney function
between the two groups to ensure the safety of the study
drug and found no difference between the two groups. In
November 2017 a total of 142 patients were active in the
study and 41 baseline biopsies had been performed. Inclu-
sion is expected to be complete by 2018.
Discussion
Long term kidney graft survival is a key issue in trans-
plant medicine. Chronic CNI nephrotoxicity contributes
to late allograft loss [3]. There is increasing evidence,
that aldosterone plays a role in detrimental processes be-
yond fluid and sodium homeostasis e.g. inflammation
and fibrosis, thereby possibly contributing to allograft
failure [7]. Several animal studies have shown an effect
of MR antagonism in reducing CNI nephrotoxicity [30].
The few available human studies addressing this hypoth-
esis have been underpowered or focused on short term
effects [19, 22]. This study aims to provide sufficiently
powered evidence regarding the effect of long term MR
antagonism on GFR and the development of kidney fi-
brosis in prevalent kidney transplant patients.
Concerns have been raised regarding MR antagonism
in patients with impaired renal function due to the risk
of hyperkalemia, which is a potentially lethal side-effect.
In the wake of the Randomized Aldactone Evaluation
Study (RALES) - a randomized, clinical trial investigating
the effect of spironolactone in patients with congestive
heart failure and serum creatinine below 221 μmol/L -
there was a significant increase in hospitalizations due to
hyperkalemia from 2.4 to 11.0 per 1000 patients [32]. The
risk of hyperkalemia increases as GFR deteriorates. One
safety study of MR antagonist eplerenone 25 mg/day for
8 weeks in 31 kidney transplant patients found a significant
increase in plasma potassium during eplerenone treatment,
however there was only one incidence of moderate hyper-
kalemia (> 5.5 mmol/L) and no patients were withdrawn
from the study due to hyperkalemia. It was concluded, that
MR antagonism is safe in kidney transplant patients
with a GFR > 30 mL/min, but warrants close monitoring
of plasma-potassium [33].
Another concern regarding MR antagonism is the ob-
servation that plasma creatinine levels tend to increase
at the initiation of therapy. This effect has also been ob-
served in studies of MR antagonism in chronic kidney
disease [34]. In RALES, spironolactone significantly in-
creased the occurrence of worsening renal function -
Table 3 Study outcomes
Primary endpoint Secondary endpoints
Chrome-EDTA clearance 24 h urinary protein excretion
Renal fibrosis (morphology)
Cardiovascular events
Biomarkers of fibrosis in tissue,
blood and urine
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defined as a reduction of eGFR> 30% - however, this did
not impact the relative mortality risk in this group. Inter-
estingly, worsening renal function was associated with an
increased adjusted mortality risk in the placebo group, but
not in the spironolactone group [35]. Although the in-
crease in plasma creatinine is reversible when MR antago-
nists are discontinued, worsening renal function poses a
diagnostic challenge with several possible etiologies in the
kidney transplant population (e.g. acute rejection, post-
renal obstruction, BK-virus nephropathy etc.). If in doubt,
MR antagonists should be discontinued and appropriate
diagnostic measures performed.
Despite potential pitfalls using MR antagonists in kid-
ney transplant patients, evidence from animal and small
human studies indicate a potential for improving long
term allograft function. This study is, to our knowledge,
the first to investigate the effect of MR antagonism on
long term allograft function in adult kidney transplant pa-
tients in a prospective, randomized fashion. Results will
contribute to current evidence and possibly influence the
future management of kidney transplant patients with
regards to improving long term allograft survival.
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